Context Therapeutics (CNTX – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Emily Bodnar today. The company’s shares closed yesterday at $0.66.
Bodnar covers the Healthcare sector, focusing on stocks such as Gracell Biotechnologies, NovoCure, and Dice Therapeutics. According to TipRanks, Bodnar has an average return of -19.5% and a 23.75% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Context Therapeutics.
See today’s best-performing stocks on TipRanks >>
Based on Context Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.85 million. In comparison, last year the company had a GAAP net loss of $1.44 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Read More on CNTX:
- Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
- Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
- Context Therapeutics highlights clinical responses from Phase 2 OATH trial
- Context Therapeutics Stock Soars on FDA Approval
